The approval is based on Moderna's phase III Coronavirus Efficacy (COVE) study results and positive initial clinical data from the Takeda-led placebo-controlled phase III study.

Takeda and Moderna previously announced that Takeda will import and distribute 50 million doses of Moderna's COVID-19 vaccine candidate starting in the first half of 2021. The companies have affirmed discussions reported recently for an additional potential supply of 50 million doses from the beginning of 2022.

Moderna booster produces antibodies against SARS-CoV-2 variants
Moderna announced that initial results from a phase II study suggest a single booster dose of its messenger RNA (mRNA) vaccine candidates mRNA-1273 or...

Moderna increases manufacturing capacity
Moderna has doubled the size of its manufacturing technology center in Norwood, MA, expanding the facility from a production and lab space into an industrial...

Moderna secures WHO emergency use listing for COVID-19 vaccine
Moderna has secured emergency use listing from the World Health Organization (WHO) for its COVID-19 vaccine.

DNA Script, Moderna to develop on-demand vaccines, therapeutics
DNA Script and Moderna have announced a partnership to develop on-demand vaccines and therapeutics as part of the U.S. Defense Advanced Research Projects...

Sanofi to provide fill/finish services for Moderna COVID-19 vaccine
Moderna has inked a new agreement with Sanofi in order to scale up U.S. manufacturing capacity for its COVID-19 vaccine.